Intraperitoneal chemotherapy in patients pretreated for ovarian cancer matched with patients treated with parenteral chemotherapy

Maria Ornella Nicoletto; Alessandra Casarin; Alessandra Baldoni; Eliana Rulli; Giulia Tasca; Zora Baretta; Grazia Artioli; Giuseppe Lombardi; Alessandro Cappetta; Irene Floriani; Giovanni Randon; Sara Valpione; Piero Litta; Pierfranco Conte; Simone Mocellin; Camillo Aliberti

Intraperitoneal chemotherapy in patients pretreated for ovarian cancer matched with patients treated with parenteral chemotherapy

Maria Ornella Nicoletto, Alessandra Casarin, Alessandra Baldoni, Eliana Rulli, Giulia Tasca, Zora Baretta, Grazia Artioli, Giuseppe Lombardi, Alessandro Cappetta, Irene Floriani, Giovanni Randon, Sara Valpione, Piero Litta, Pierfranco Conte, Simone Mocellin, Camillo Aliberti

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Our aim was to analyze the impact of intraperitoneal chemotherapy (IPC), administered with direct peritoneal puncture, on the survival of patients with pretreated ovarian cancer in a real-life setting. Patients and Methods: This was a retrospective study comparing patients with advanced ovarian cancer treated with IPC (N=33) and patients treated with standard intravenous (i.v.) chemotherapy matching cases for known prognostic factors (age, platinum sensitivity, histological subgroup and grade). Data were then analyzed for survival with nested Cox multivariate regression. Results: The case matching resulted in two homogeneous cohorts by age, platinum sensitivity, resistance to therapy and histology. When analyzed by hazard ratio (HR), the number of previous treatments and IPC vs. i.v. therapy were significant (HR=1.97 for i.v. and HR=1.90 for each incremental previous treatment line, multivariate p

Original language	Italian
Pages (from-to)	6541-6546
Number of pages	6
Journal	Anticancer Research
Volume	36
Issue number	12
Publication status	Published - Dec 1 2016

Access to Document

Cite this

Nicoletto, M. O., Casarin, A., Baldoni, A., Rulli, E., Tasca, G., Baretta, Z., Artioli, G., Lombardi, G., Cappetta, A., Floriani, I., Randon, G., Valpione, S., Litta, P., Conte, P., Mocellin, S., & Aliberti, C. (2016). Intraperitoneal chemotherapy in patients pretreated for ovarian cancer matched with patients treated with parenteral chemotherapy. Anticancer Research, 36(12), 6541-6546. http://www.scopus.com/inward/record.url?scp=85001950479&partnerID=8YFLogxK

Nicoletto, MO, Casarin, A, Baldoni, A, Rulli, E, Tasca, G, Baretta, Z, Artioli, G, Lombardi, G, Cappetta, A, Floriani, I, Randon, G, Valpione, S, Litta, P, Conte, P , Mocellin, S & Aliberti, C 2016, 'Intraperitoneal chemotherapy in patients pretreated for ovarian cancer matched with patients treated with parenteral chemotherapy', Anticancer Research, vol. 36, no. 12, pp. 6541-6546. <http://www.scopus.com/inward/record.url?scp=85001950479&partnerID=8YFLogxK>

@article{8f1be958988f47f1ab981b75bfb296cc,

title = "Intraperitoneal chemotherapy in patients pretreated for ovarian cancer matched with patients treated with parenteral chemotherapy",

abstract = "Background: Our aim was to analyze the impact of intraperitoneal chemotherapy (IPC), administered with direct peritoneal puncture, on the survival of patients with pretreated ovarian cancer in a real-life setting. Patients and Methods: This was a retrospective study comparing patients with advanced ovarian cancer treated with IPC (N=33) and patients treated with standard intravenous (i.v.) chemotherapy matching cases for known prognostic factors (age, platinum sensitivity, histological subgroup and grade). Data were then analyzed for survival with nested Cox multivariate regression. Results: The case matching resulted in two homogeneous cohorts by age, platinum sensitivity, resistance to therapy and histology. When analyzed by hazard ratio (HR), the number of previous treatments and IPC vs. i.v. therapy were significant (HR=1.97 for i.v. and HR=1.90 for each incremental previous treatment line, multivariate p",

keywords = "Intraperitoneal treatment, Parenteral chemotherapy, Pretreated ovarian cancer",

author = "Nicoletto, {Maria Ornella} and Alessandra Casarin and Alessandra Baldoni and Eliana Rulli and Giulia Tasca and Zora Baretta and Grazia Artioli and Giuseppe Lombardi and Alessandro Cappetta and Irene Floriani and Giovanni Randon and Sara Valpione and Piero Litta and Pierfranco Conte and Simone Mocellin and Camillo Aliberti",

year = "2016",

month = dec,

day = "1",

language = "Italian",

volume = "36",

pages = "6541--6546",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "12",

}

TY - JOUR

T1 - Intraperitoneal chemotherapy in patients pretreated for ovarian cancer matched with patients treated with parenteral chemotherapy

AU - Nicoletto, Maria Ornella

AU - Casarin, Alessandra

AU - Baldoni, Alessandra

AU - Rulli, Eliana

AU - Tasca, Giulia

AU - Baretta, Zora

AU - Artioli, Grazia

AU - Lombardi, Giuseppe

AU - Cappetta, Alessandro

AU - Floriani, Irene

AU - Randon, Giovanni

AU - Valpione, Sara

AU - Litta, Piero

AU - Conte, Pierfranco

AU - Mocellin, Simone

AU - Aliberti, Camillo

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background: Our aim was to analyze the impact of intraperitoneal chemotherapy (IPC), administered with direct peritoneal puncture, on the survival of patients with pretreated ovarian cancer in a real-life setting. Patients and Methods: This was a retrospective study comparing patients with advanced ovarian cancer treated with IPC (N=33) and patients treated with standard intravenous (i.v.) chemotherapy matching cases for known prognostic factors (age, platinum sensitivity, histological subgroup and grade). Data were then analyzed for survival with nested Cox multivariate regression. Results: The case matching resulted in two homogeneous cohorts by age, platinum sensitivity, resistance to therapy and histology. When analyzed by hazard ratio (HR), the number of previous treatments and IPC vs. i.v. therapy were significant (HR=1.97 for i.v. and HR=1.90 for each incremental previous treatment line, multivariate p

AB - Background: Our aim was to analyze the impact of intraperitoneal chemotherapy (IPC), administered with direct peritoneal puncture, on the survival of patients with pretreated ovarian cancer in a real-life setting. Patients and Methods: This was a retrospective study comparing patients with advanced ovarian cancer treated with IPC (N=33) and patients treated with standard intravenous (i.v.) chemotherapy matching cases for known prognostic factors (age, platinum sensitivity, histological subgroup and grade). Data were then analyzed for survival with nested Cox multivariate regression. Results: The case matching resulted in two homogeneous cohorts by age, platinum sensitivity, resistance to therapy and histology. When analyzed by hazard ratio (HR), the number of previous treatments and IPC vs. i.v. therapy were significant (HR=1.97 for i.v. and HR=1.90 for each incremental previous treatment line, multivariate p

KW - Intraperitoneal treatment

KW - Parenteral chemotherapy

KW - Pretreated ovarian cancer

M3 - Articolo

VL - 36

SP - 6541

EP - 6546

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -